
Takeda launches Orzeyful in Japan and China for narcolepsy type 1
China’s indication includes patients aged 16 and older, while Japan’s covers adults; U.S. availability is expected in November after DEA scheduling.

The multiyear partnership adds deployment and operations support as Axe works to bring more than US$3.45B of customer projects into production.

China’s indication includes patients aged 16 and older, while Japan’s covers adults; U.S. availability is expected in November after DEA scheduling.

The financing adds 4.99 million shares for East Sudbury work, while final closing remains subject to TSX Venture Exchange acceptance.
The approval adds adults with high-grade, BCG-unresponsive disease ahead of the Jan. 6, 2027 review target.
Cash is payable at closing, subject to antitrust conditions; two announced voucher agreements total US$413 million.

A 70.10-metre intercept could reduce waste mining at Gabbs, where a feasibility study is targeted for the first quarter of 2027.

Consolidated copper output was flat at 205,000 tonnes in the third quarter, while the Mongolian operation ran at an annualised 450,000 tonnes.

The 13-person study had no control group and a safety primary endpoint, with a separate CVID readout expected in November.

The court awarded appeal costs; the A$7.40-a-share deal was terminated in December 2025, and Mayne is pursuing damages.
The Nigerian mine poured 15,515 ounces in the third quarter, while Thor maintained its C$0.0125 quarterly dividend.
The proposed project debt awaits lender diligence and final documents as Phase 1 completion remains targeted for December 2026.
INFARMED authorized microbiological and chemical/physical tests at Cantanhede, where Tilray expects faster batch releases and lower costs.
Myriad would issue 1,571,268 shares, while Green Shift would retain a 2 per cent royalty with a partial buyback right.
The Nevada silver explorer staked 382 claims after a May survey outlined silver anomalies and possible copper-silver-gold porphyries.
BP flags US$3B to US$4.5B in total post-tax impairments, primarily attributable to transition businesses, ahead of Oct. 30 results.
The estimated true width is 95.3 metres, and the new assays mark the planned data cut-off for an estimate expected in the December quarter.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The sub-level cave is expected to sustain pellet supply through 2035, funded from existing cash reserves and open-pit cash flows.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The Oct. 7 letter addresses quality-system responses, while Olympus says it brings no new production or distribution restrictions.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
Five million proposed shares carry a US$100 stated amount, while the preliminary prospectus leaves the sale price and fees blank.
Germany's Tübingen authority certified softgel manufacturing and primary packaging of softgels, oral liquids and dried cannabis flower.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
Volumes are 70 per cent above the May term sheet and will ramp up as Nolans reaches nameplate production.

Equinor keeps 70 per cent and expects first oil in 2031; its project page estimates C$14 billion in initial investment.

FERC set an Oct. 22 intervention deadline as NGPL seeks 321,200 dekatherms a day of new capacity for power generation.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The Sept. 30 balance is up 7.4 per cent from a year earlier; the client deposits are held at Safe Harbor's partner financial institutions.

The linked customer page carries Oct. 9 closing notices for 13 Florida stores and does not give individual reopening dates.

The Oct. 9 joint filing asks the D.C. Circuit to adopt Feb. 19, 2027, as the final briefing date for three consolidated petitions for review.

The Oct. 9 filing follows a July deal to issue 0.015383618 Vireo share per eligible Planet 13 share, subject to shareholder and regulatory approvals.